Pnd150 - Impact of Inotersen on Condition-Specific Quality of Life (Qol) for Patients With Hattr Amyloidosis: Results From a Double-Blind Placebo-Controlled Trial

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2898
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy